Camozzi joins AMT on 18 July from Orphan Europe, where he held the position of medical director for more than five years. Prior to this, he was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities.
From 2001–2005, Camozzi was md of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programmes for pharmaceutical and healthcare products.
Dr Camozzi started his career in South America holding roles at Lederle/American Cyanamid and F Hoffmann La-Roche.
Amsterdam Molecular Therapeutics appoints chief medical officer
Dutch human gene therapy specialist hires Carlos Camozzi
You may also like
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
![Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker]()
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
![BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset]()
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset
The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
![Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration]()
Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration
Mabion has signed a letter of intent with Oddifact to reposition its Phase III-stage CD20 monoclonal antibody candidate for rare disease indications, leveraging AI-driven orphan drug identification and existing manufacturing expertise
